Cargando…

Concomitant Ruxolitinib and Ibrutinib for Graft-Versus-Host Disease (GVHD): The First Reported Use in Pediatric Patients

Allogeneic hematopoietic stem cell transplant (alloHSCT) can be a life-saving treatment for patients with hematological disorders but far too often carries the feared complication of graft-versus-host disease (GVHD). The first-line treatment of GVHD is typically corticosteroids, but steroid-refracto...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gagliardi, Thomas A, Milner, Jordan, Cairo, Mitchell S, Steinberg, Amir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2022
Materias:	Pediatrics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573080/ https://www.ncbi.nlm.nih.gov/pubmed/36258935 http://dx.doi.org/10.7759/cureus.29195

Ejemplares similares

Is It Possible to Separate the Graft-Versus-Leukemia (GVL) Effect Against B Cell Acute Lymphoblastic Leukemia From Graft-Versus-Host Disease (GVHD) After Hematopoietic Cell Transplant?
por: Rozmus, Jacob, et al.
Publicado: (2022)

Ruxolitinib for Therapy of Graft-versus-Host Disease
por: Neumann, Thomas, et al.
Publicado: (2019)

Immunometabolic Therapeutic Targets of Graft-versus-Host Disease (GvHD)
por: Mhandire, Kudakwashe, et al.
Publicado: (2021)

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
por: von Bubnoff, Nikolas, et al.
Publicado: (2018)

The Role of Myeloid-Derived Suppressor Cells (MDSCs) in Graft-versus-Host Disease (GVHD)
por: Demosthenous, Christos, et al.
Publicado: (2021)

Serum MicroRNA-155 in Acute Graft-Versus-Host-Disease (aGVHD)
por: Efebera, Yvonne A, et al.
Publicado: (2019)

Editorial: Novel and Improved Methods for the Prevention and Treatment of Graft-Versus-Host Disease (GVHD)
por: Ullrich, Evelyn, et al.
Publicado: (2022)

Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD
por: Sobash, Philip T., et al.
Publicado: (2020)

Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands
por: Jansen, Jeroen P., et al.
Publicado: (2010)

Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
por: Kaloyannidis, Panayotis, et al.
Publicado: (2018)

Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib
por: Rodríguez-Gil, Alfonso, et al.
Publicado: (2022)

Alemtuzumab as graft-versus-host disease (GVHD) prophylaxis strategy in a developing country: lower rate of acute GVHD, increased risk of cytomegalovirus reactivation
por: Resende, C.B., et al.
Publicado: (2017)

Risk and promise: an 11-year, single-center retrospective study of severe acute GVHD in pediatric patients undergoing allogeneic HSCT for nonmalignant diseases
por: Zaidman, Irina, et al.
Publicado: (2023)

Life-Threatening Hypertriglyceridemia in a Patient on Ruxolitinib and Sirolimus for Chronic Graft-versus-Host Disease
por: Watson, Allison P., et al.
Publicado: (2018)

Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study
por: Escamilla Gómez, Virginia, et al.
Publicado: (2019)

The Effectiveness of Ruxolitinib for Acute/Chronic Graft-versus-Host Disease in Children: A Retrospective Study
por: Yang, Wenli, et al.
Publicado: (2021)

Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis
por: Fan, Shuang, et al.
Publicado: (2022)

Hydrogen therapy may be an effective and specific novel treatment for Acute Graft-versus-host disease (GVHD)
por: Qian, Liren, et al.
Publicado: (2013)

Allodepleted T‐cell immunotherapy after haploidentical haematopoietic stem cell transplantation without severe acute graft‐versus‐host disease (GVHD) in the absence of GVHD prophylaxis
por: Roy, Denis Claude, et al.
Publicado: (2019)

Editorial on Translational Research in Graft-Versus-Host Disease (GVHD) and Graft-Versus-Tumor (GVT) Effect After Allogeneic Hematopoietic Cell Transplantation
por: Czech, Marie, et al.
Publicado: (2022)

Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice
por: Schutt, Steven D., et al.
Publicado: (2015)

Serotherapy as Graft-Versus-Host Disease Prophylaxis in Haematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukaemia
por: Keogh, Steven J., et al.
Publicado: (2022)

Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease
por: Wang, Dong, et al.
Publicado: (2021)

Thiol/Redox Metabolomic Profiling Implicates GSH Dysregulation in Early Experimental Graft versus Host Disease (GVHD)
por: Suh, Jung H., et al.
Publicado: (2014)

Cytokine and human leukocyte antigen (HLA) profile for graft-versus-host disease (GVHD) after organ transplantation
por: Chen, Xinhua, et al.
Publicado: (2016)

Self-retained cryopreserved amniotic membrane in treating acute ocular graft-versus-host-disease (oGVHD)
por: Yin, Han Y., et al.
Publicado: (2020)

(18)F-FDG-PET-MRI for the assessment of acute intestinal graft-versus-host-disease (GvHD)
por: Roll, Wolfgang, et al.
Publicado: (2021)

Chronic Graft-Versus-Host Disease (cGVHD) Exacerbation after Sars-Cov-2 Covid Vaccination
por: Trunk, Andrew D., et al.
Publicado: (2021)

Bamlanivimab Monoclonal Antibody Treatment in Patients with Graft Versus Host Disease (GVHD) Diagnosed with COVID-19 Infection
por: Faisal, Muhammad Salman, et al.
Publicado: (2022)

Development and validation of a diagnostic model for the identification of chronic ocular graft-versus-host disease (oGVHD)
por: Shen, Zhan, et al.
Publicado: (2023)

Case report: Durable response to ruxolitinib in a child with TREX1-related disorder
por: Bin Khathlan, Yasir, et al.
Publicado: (2023)

Comparative Effectiveness of Remestemcel-L-rknd versus Ruxolitinib in Pediatric Patients with Steroid-Refractory Acute Graft-Versus-Host Disease using Simulated Treatment Comparisons
por: Tremblay, Gabriel, et al.
Publicado: (2021)

Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD
por: Liu, Yin, et al.
Publicado: (2022)

International Chronic Ocular Graft-vs-Host-Disease (GVHD) Consensus Group: Proposed Diagnostic Criteria for Chronic GVHD (Part I)
por: Ogawa, Yoko, et al.
Publicado: (2013)

Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis
por: Sarmiento Maldonado, Mauricio, et al.
Publicado: (2017)

Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients
por: Wei, Cong, et al.
Publicado: (2021)

Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement
por: Kaurinovic, Martina, et al.
Publicado: (2022)

PB2457: RUXOLITINIB AS TREATMENT IN PATIENTS WITH ACUTE AND CRONIC GRAFT-VERSUS-HOST DISEASE. REAL WORLD EVIDENCE
por: José Jiménez Nájar, Francisco, et al.
Publicado: (2023)

Ruxolitinib improves hematopoietic regeneration by restoring mesenchymal stromal cell function in acute graft-versus-host disease
por: Lin, Yan, et al.
Publicado: (2023)

Colon biopsies for evaluation of acute graft-versus-host disease (A-GVHD) in allogeneic bone marrow transplant patients
por: Shidham, Vinod B, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_5fsfn7qmariv98qc94qvkj8qd2